替诺福韦、妊娠及 HIV 感染孕妇肾功能变化。
Tenofovir, pregnancy and renal function changes in pregnant women living with HIV.
机构信息
Department of Gynecology and Obstetrics.
Division of Maternal Fetal Medicine and Clinical Pharmacology, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
AIDS. 2021 Jul 1;35(8):1319-1320. doi: 10.1097/QAD.0000000000002880.
Abstract
This retrospective study of 100 pregnant women living with HIV [66 on tenofovir disoproxil fumarate (TDF) compared to 34 women on tenofovir alafenamide (TAF)] found no significant difference in renal function in pregnant women with HIV receiving TDF versus TAF. Our results demonstrate that, in regard to renal toxicity, both TDF and TAF appear to be safe for pregnant women living with HIV, but larger prospective cohort studies in pregnant women living with HIV are encouraged.
摘要
本回顾性研究纳入了 100 名 HIV 阳性孕妇[66 名接受富马酸替诺福韦二吡呋酯（TDF）治疗，34 名接受替诺福韦艾拉酚胺（TAF）治疗]，结果发现，接受 TDF 或 TAF 治疗的 HIV 阳性孕妇的肾功能无显著差异。我们的研究结果表明，在肾毒性方面，TDF 和 TAF 似乎对 HIV 阳性孕妇都是安全的，但仍鼓励开展针对 HIV 阳性孕妇的更大规模前瞻性队列研究。
相似文献
1
Tenofovir, pregnancy and renal function changes in pregnant women living with HIV.替诺福韦、妊娠及 HIV 感染孕妇肾功能变化。
AIDS. 2021 Jul 1;35(8):1319-1320. doi: 10.1097/QAD.0000000000002880.
2
Tenofovir alafenamide use in pregnant and lactating women living with HIV.替诺福韦艾拉酚胺在感染HIV的孕妇和哺乳期妇女中的应用。
Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):333-342. doi: 10.1080/17425255.2020.1738384. Epub 2020 Mar 17.
3
Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.接受替诺福韦艾拉酚胺和富马酸替诺福韦二吡呋酯治疗的HIV感染孕妇的依从性预测因素
J Pharm Drug Res. 2022;5(1):585-593. Epub 2022 Jul 2.
4
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.含替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯的固定剂量单片复方制剂治疗初治 HIV-1 感染的疗效和安全性：一项随机对照试验的荟萃分析。
Int J Infect Dis. 2020 Apr;93:108-117. doi: 10.1016/j.ijid.2020.01.035. Epub 2020 Jan 25.
5
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.在 HIV 感染者中，从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺后的体重和代谢变化：一项队列研究。
Ann Intern Med. 2021 Jun;174(6):758-767. doi: 10.7326/M20-4853. Epub 2021 Mar 16.
6
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.在瑞士艾滋病毒队列研究中，未患有病毒性肝炎的 HIV 阳性人群中，从富马酸替诺福韦二吡呋酯（TDF）转换为替诺福韦艾拉酚胺（TAF）后丙氨酸氨基转移酶水平的变化。
HIV Med. 2021 Aug;22(7):623-628. doi: 10.1111/hiv.13106. Epub 2021 Apr 20.
7
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.富马酸替诺福韦艾拉酚胺的治疗会恶化感染 HIV 患者的血脂水平，与富马酸替诺福韦二吡呋酯联合艾维雷韦、考比司他和恩曲他滨的治疗相比。
Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479-490. doi: 10.1111/bcpt.13161. Epub 2018 Dec 7.
8
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.在成人人类免疫缺陷病毒（HIV）感染者中，从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺后的代谢相关结局：一项多中心前瞻性队列研究。
Clin Infect Dis. 2023 Feb 8;76(3):e652-e660. doi: 10.1093/cid/ciac621.
9
Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.在大都市性健康服务机构的 HIV 阳性患者中，将富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺后肾功能的变化。
AIDS Res Ther. 2019 Dec 7;16(1):40. doi: 10.1186/s12981-019-0256-9.
10
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.妊娠和伴随抗逆转录病毒药物对接受富马酸替诺福韦二吡呋酯为基础的抗逆转录病毒治疗的 HIV 感染妇女与接受富马酸替诺福韦二吡呋酯单药治疗的 HBV 感染妇女中替诺福韦的药代动力学的影响。
J Clin Pharmacol. 2021 Mar;61(3):388-393. doi: 10.1002/jcph.1746. Epub 2020 Sep 22.
引用本文的文献
1
Pharmacokinetic Adaptations in Pregnancy: Implications for Optimizing Antiretroviral Therapy in HIV-Positive Women.孕期的药代动力学适应性：对优化HIV阳性女性抗逆转录病毒治疗的意义
Pharmaceutics. 2025 Jul 15;17(7):913. doi: 10.3390/pharmaceutics17070913.
2
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy.接受基于替诺福韦的抗逆转录病毒治疗的HIV感染孕妇的血脂和血糖状况
Clin Infect Dis. 2025 Mar 17;80(3):594-601. doi: 10.1093/cid/ciae441.
3
Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature.妊娠期抗逆转录病毒治疗：文献 2023 年回顾。
Curr HIV/AIDS Rep. 2024 Feb;21(1):1-10. doi: 10.1007/s11904-024-00688-y. Epub 2024 Jan 26.
4
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection.扩大替诺福韦艾拉酚胺在治疗和预防 HIV-1 感染方面的应用。
Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(10):939-957. doi: 10.1080/17512433.2023.2251387. Epub 2023 Sep 7.
5
Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women.了解涉及抗逆转录病毒初治和经验丰富妇女的 HIV 妊娠研究中报告的临床结局指标。
Lancet Infect Dis. 2023 Apr;23(4):e151-e159. doi: 10.1016/S1473-3099(22)00687-9. Epub 2022 Nov 11.
6
Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.接受替诺福韦艾拉酚胺和富马酸替诺福韦二吡呋酯治疗的HIV感染孕妇的依从性预测因素
J Pharm Drug Res. 2022;5(1):585-593. Epub 2022 Jul 2.
Zotero 插件